News coverage about Ekso Bionics Holdings (NASDAQ:EKSO) has been trending somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ekso Bionics Holdings earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.5762759218046 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

A number of brokerages have issued reports on EKSO. B. Riley reiterated a “buy” rating and set a $4.00 price target on shares of Ekso Bionics Holdings in a research report on Monday, May 15th. Zacks Investment Research downgraded Ekso Bionics Holdings from a “buy” rating to a “hold” rating in a research report on Friday, June 16th.

Shares of Ekso Bionics Holdings (NASDAQ EKSO) traded up 5.44% during trading on Monday, reaching $1.55. The company’s stock had a trading volume of 405,512 shares. The firm’s market capitalization is $39.73 million. The company has a 50 day moving average price of $1.99 and a 200 day moving average price of $2.64. Ekso Bionics Holdings has a 52 week low of $0.99 and a 52 week high of $6.38.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.